Detalles de la búsqueda
1.
Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Alzheimers Dement;
19(6): 2497-2507, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36516028
2.
Robustness of CSF Aß42/40 and Aß42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
Alzheimers Dement;
19(7): 2994-3004, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36681387
3.
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
Alzheimers Dement;
19(7): 2943-2955, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648169
4.
Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models.
Alzheimers Dement;
2022 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35699240
5.
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease.
Curr Opin Neurol;
34(2): 266-274, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33470669
6.
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease.
Acta Neuropathol;
137(1): 89-102, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30244311
7.
Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.
Acta Neuropathol;
137(2): 279-296, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30547227
8.
Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury.
Clin Chem Lab Med;
57(10): 1565-1573, 2019 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-30980710
9.
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.
Acta Neuropathol;
136(3): 363-376, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29700597
10.
Transient increase in CSF GAP-43 concentration after ischemic stroke.
BMC Neurol;
18(1): 202, 2018 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30526557
11.
Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial.
EBioMedicine;
99: 104923, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101301
12.
A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings.
Nat Commun;
15(1): 2311, 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38486040
13.
Plasma amyloid-ß42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease.
Brain Commun;
5(2): fcad015, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36926368
14.
A two-step workflow based on plasma p-tau217 to screen for amyloid ß positivity with further confirmatory testing only in uncertain cases.
Nat Aging;
3(9): 1079-1090, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37653254
15.
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
JAMA Neurol;
79(2): 149-158, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34928318
16.
Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
Sci Rep;
11(1): 1965, 2021 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33479445
17.
Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.
Nat Commun;
12(1): 3555, 2021 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117234
18.
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations.
Nat Aging;
1(1): 114-123, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37117993
19.
The ANTsX ecosystem for quantitative biological and medical imaging.
Sci Rep;
11(1): 9068, 2021 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33907199
20.
Comparing progression biomarkers in clinical trials of early Alzheimer's disease.
Ann Clin Transl Neurol;
7(9): 1661-1673, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32779869